A novel high throughput 1536-well notch1 γsecretase AlphaLISA assay

Combinatorial Chemistry and High Throughput Screening

Volumn 16, Issue 6, 2013, Pages 415-424

  Chau, De Ming ^a,c   Shum, David ^a,b   Radu, Constantin ^a,b   Bhinder, Bhavneet ^a,b   Gin, David ^a,d   Gilchrist, M Lane ^e   Djaballah, Hakim ^a,b   Li, Yue Ming ^a,b,c  

^a Molecular Pharmacology and Chemistry Program   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Weill Cornell Graduate School of Biomedical Sciences   (United States)

^d CITY COLLEGE OF NEW YORK   (United States)

^e City University of New York   (United States)

Author keywords

secretase; secretase modulators; AlphaLISA; Alzheimer disease; Cancer; Notch signaling

Indexed keywords

CALPEPTIN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; KD I 085; NOTCH1 RECEPTOR; POLYCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALPHALISA ASSAY; ALZHEIMER DISEASE; ARTICLE; CHEMOLUMINESCENCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; IMMUNOASSAY; IN VITRO STUDY; INFORMATION PROCESSING; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR SOLUBILIZATION; RELIABILITY; REPRODUCIBILITY; SIGNAL NOISE RATIO; SIGNAL TRANSDUCTION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIGH-THROUGHPUT SCREENING ASSAYS; MOLECULAR STRUCTURE; RECEPTOR, NOTCH1; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84877951060     PISSN: 13862073     EISSN: 18755402     Source Type: Journal    
DOI: 10.2174/1386207311316060001     Document Type: Article

References (42)

1. Selkoe, D.J.; Wolfe, M.S. Presenilin: running with scissors in the membrane. Cell, 2007, 131, 215-521.
2. Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002, 297, 353-356.
3. Artavanis-Tsakonas, S.; Rand, M.D.; Lake, R.J. Notch signaling: cell fate control and signal integration in development. Science, 1999, 284, 770-776.
4. Kopan, R.; Goate, A. A common enzyme connects notch signaling and Alzheimer's disease. Genes Dev., 2000, 14, 2799-806.
5. Kopan, R.; Ilagan, M.X. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell, 2009, 137, 216-233.
6. Gridley, T. Notch signaling and inherited disease syndromes. Hum. Mol. Genet., 2003, 12 Spec No 1, R9-13.
7. Koch, U.; Radtke, F. Notch and cancer: a double-edged sword. Cell Mol. Life Sci., 2007, 64, 2746-2762.
8. Lathia, J.D.; Mattson, M.P.; Cheng, A. Notch: from neural development to neurological disorders. J. Neurochem., 2008, 107, 1471-14.
9. Lasky, J.L.; Wu, H. Notch signaling, brain development, and human disease. Pediatr. Res., 2005, 57, 104R-109R.
10. Li, Y.M.; Lai, M.T.; Xu, M.; Huang, Q.; DiMuzio-Mower, J.; Sardana, M.K.; Shi, X.P.; Yin, K.C.; Shafer, J.A.; Gardell, S.J. Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state. Proc Natl. Acad Sci. U S A, 2000, 97, 6138-6143.
11. Shearman, M.S.; Beher, D.; Clarke, E.E.; Lewis, H.D.; Harrison, T.; Hunt, P.; Nadin, A.; Smith, A.L.; Stevenson, G.; Castro, J.L. L- 685, 458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity. Biochemistry, 2000, 39, 8698-8704.
12. McLendon, C.; Xin, T.; Ziani-Cherif, C.; Murphy, M.P.; Findlay, K.A.; Lewis, P.A.; Pinnix, I.; Sambamurti, K.; Wang, R.; Fauq, A.; Golde, T.E. Cell-free assays for gamma-secretase activity. FASEB J., 2000, 14, 2383-8236.
13. Karlstrom, H.; Bergman, A.; Lendahl, U.; Naslund, J.; Lundkvist, J. A sensitive and quantitative assay for measuring cleavage of presenilin substrates. J. Biol. Chem., 2002, 277, 6763-6766.
14. Bakshi, P.; Liao, Y.F.; Gao, J.; Ni, J.; Stein, R.; Yeh, L.A.; Wolfe, M.S. A high throughput screen to identify inhibitors of amyloid beta-protein precursor processing. J. Biomol. Screen., 2005, 10, 1- 12.
15. Jensen, M.; Hartmann, T.; Engvall, B.; Wang, R.; Uljon, S.N.; Sennvik, K.; Naslund, J.; Muehlhauser, F.; Nordstedt, C.; Beyreuther, K.; Lannfelt, L. Quantification of Alzheimer amyloid beta peptides ending at residues 40 and 42 by novel ELISA systems. Mol. Med., 2000, 6, 291-302.
16. Clarke, E.E.; Shearman, M.S. Quantitation of amyloid-beta peptides in biological milieu using a novel homogeneous timeresolved fluorescence (HTRF) assay. J. Neurosci. Methods, 2000, 102, 61-68.
17. Szekeres, P.G.; Leong, K.; Day, T.A.; Kingston, A.E.; Karran, E.H. Development of homogeneous 384-well high throughput screening assays for Abeta1-40 and Abeta1-42 using AlphaScreen technology. J. Biomol. Screen., 2008, 13, 101-111.
18. Shelton, C.C.; Tian, Y.; Shum, D.; Radu, C.; Djaballah, H.; Li, Y.M. A miniaturized 1536-well format gamma-secretase assay. Assay Drug Dev Technol, 2009, 7, 461-470.
19. Shelton, C.C.; Zhu, L.; Chau, D.; Yang, L.; Wang, R.; Djaballah, H.; Zheng, H.; Li, Y.M. Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc. Natl. Acad Sci. U S A, 2009, 106, 20228-20233.
20. Chau, D.M.; Crump, C.J.; Villa, J.C.; Scheinberg, D.A.; Li, Y.M. Familial Alzheimer Disease Presenilin-1 Mutations Alter the Active Site Conformation of gamma-secretase. J. Biol. Chem., 2012, 287, 17288-17296.
21. Crump, C.J.; Castro, S.V.; Wang, F.; Pozdnyakov, N.; Ballard, T.E.; Sisodia, S.S.; Bales, K.R.; Johnson, D.S. and Li, Y.M. BMS- 708, 163 Targets Presenilin and Lacks Notch-Sparing Activity. Biochemistry, 2012, 51, 7209-7211.
22. Eglen, R.M.; Reisine, T.; Roby, P.; Rouleau, N.; Illy, C.; Bosse, R.; Bielefeld, M. The use of AlphaScreen technology in HTS: current status. Curr. Chem. Genomics, 2008, 1, 2-10.
23. Seideman, J.H.; Shum, D.; Djaballah, H.; Scheinberg, D.A. A high throughput screen for alpha particle radiation protectants. Assay Drug Dev. Technol., 2010, 8, 602-614.
24. Antczak, C.; Mahida, J.P.; Bhinder, B.; Calder, P.A.; Djaballah, H. A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery. J. Biomol. Screen., 2012, 17, 885-899.
25. Tseng, H.M.; Shum, D.; Bhinder, B.; Escobar, S.; Veomett, N.J.; Tomkinson, A.E.; Gin, D.Y.; Djaballah, H.; Scheinberg, D.A. A high throughput scintillation proximity-based assay for human DNA ligase IV. Assay Drug Dev. Technol., 2012, 10, 235-249.
26. Shum, D.; Bhinder, B.; Radu, C.; Calder, P.; Ramirez, C.N.; Djaballah, H. An image-based biosensor assay strategy to screen for modulators of the microRNA 21 biogenesis pathway. Comb. Chem. High Throughput Screen., 2012, 15, 529-541.
27. Takagi, T.; Shum, D.; Parisi, M.; Santos, R.E.; Radu, C.; Calder, P.; Rizvi, Z.; Frattini, M.G.; Djaballah, H. Comparison of luminescence ADP production assay and radiometric scintillation proximity assay for Cdc7 kinase. Comb. Chem. High Throughput Screen., 2011, 14, 669-687.
28. Lee, G.; Ramirez, C.N.; Kim, H.; Zeltner, N.; Liu, B.; Radu, C.; Bhinder, B.; Kim, Y.J.; Choi, I.Y.; Mukherjee-Clavin, B.; Djaballah, H.; Studer, L. Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. Nat. Biotechnol., 2012, 30, 1244- 1248.
29. Zhang, J.H.; Chung, T.D.; Oldenburg, K.R. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J. Biomol. Screen., 1999, 4, 67-73.
30. Seiffert, D.; Bradley, J.D.; Rominger, C.M.; Rominger, D.H.; Yang, F.; Meredith, J.E.; Jr. Wang, Q.; Roach, A.H.; Thompson, L.A.; Spitz, S.M.; Higaki, J.N.; Prakash, S.R.; Combs, A.P.; Copeland, R.A.; Arneric, S.P.; Hartig, P.R.; Robertson, D.W.; Cordell, B.; Stern, A.M.; Olson, R.E.; Zaczek, R. Presenilin-1 and - 2 are molecular targets for gamma-secretase inhibitors. J. Biol. Chem., 2000, 275, 34086-34091.
31. Dovey, H.F.; John, V.; Anderson, J.P.; Chen, L.Z.; de Saint Andrieu, P.; Fang, L.Y.; Freedman, S.B.; Folmer, B.; Goldbach, E.; Holsztynska, E.J.; Hu, K.L.; Johnson-Wood, K.L.; Kennedy, S.L.; Kholodenko, D.; Knops, J.E.; Latimer, L.H.; Lee, M.; Liao, Z.; Lieberburg, I.M.; Motter, R.N.; Mutter, L.C.; Nietz, J.; Quinn, K.P.; Sacchi, K.L.; Seubert, P.A.; Shopp, G.M.; Thorsett, E.D.; Tung, J.S.; Wu, J.; Yang, S.; Yin, C.T.; Schenk, D.B.; May, P.C.; Altstiel, L.D.; Bender, M.H.; Boggs, L.N.; Britton, T.C.; Clemens, J.C.; Czilli, D.L.; Dieckman-McGinty, D.K.; Droste, J.J.; Fuson, K.S.; Gitter, B.D.; Hyslop, P.A.; Johnstone, E.M.; Li, W.Y.; Little, S.P.; Mabry, T.E.; Miller, F.D.; Audia, J.E. Functional gammasecretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem., 2001, 76, 173-181.
32. Kanungo, J.; Zheng, Y.L.; Amin, N.D.; Pant, H.C. The Notch signaling inhibitor DAPT down-regulates cdk5 activity and modulates the distribution of neuronal cytoskeletal proteins. J. Neurochem., 2008, 106, 2236-2248.
33. Schroeter, E.H.; Ilagan, M.X.; Brunkan, A.L.; Hecimovic, S.; Li, Y.M.; Xu, M.; Lewis, H.D.; Saxena, M.T.; De Strooper, B.; Coonrod, A.; Tomita, T.; Iwatsubo, T.; Moore, C.L.; Goate, A.; Wolfe, M.S.; Shearman, M.; Kopan, R. A presenilin dimer at the core of the gamma-secretase enzyme: insights from parallel analysis of Notch 1 and APP proteolysis. Proc. Natl. Acad Sci. U S A, 2003, 100, 13075-13080.
34. Mumm, J.S.; Schroeter, E.H.; Saxena, M.T.; Griesemer, A.; Tian, X.; Pan, D.J.; Ray, W.J.; Kopan, R. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1. Mol. Cell, 2000, 5, 197-206.
35. Tian, Y.; Bassit, B.; Chau, D.; Li, Y.M. An APP inhibitory domain containing the Flemish mutation modulates -secretase activity. Nat Struct Mol Biol 2009, in press.
36. Muller, U.C.; Zheng, H. Physiological Functions of APP Family Proteins. Cold Spring Harb. Perspect Med., 2012, 2, a006288.
37. Olson, R.E.; Albright, C.F. Recent progress in the medicinal chemistry of gamma-secretase inhibitors. Curr. Top Med. Chem., 2008, 8, 17-33.
38. Kreft, A.F.; Martone, R.; Porte, A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J. Med. Chem., 2009, 52, 6169-6188.
39. Siemers, E.; Skinner, M.; Dean, R.A.; Gonzales, C.; Satterwhite, J.; Farlow, M.; Ness, D.; May, P.C. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gammasecretase inhibitor in volunteers. Clin. Neuropharmacol., 2005, 28, 126-132.
40. Martone, R.L.; Zhou, H.; Atchison, K.; Comery, T.; Xu, J.Z.; Huang, X.; Gong, X.; Jin, M.; Kreft, A.; Harrison, B.; Mayer, S.C.; Aschmies, S.; Gonzales, C.; Zaleska, M.M.; Riddell, D.R.; Wagner, E.; Lu, P.; Sun, S.C.; Sonnenberg-Reines, J.; Oganesian, A.; Adkins, K.; Leach, M.W.; Clarke, D.W.; Huryn, D.; Abou-Gharbia, M.; Magolda, R.; Bard, J.; Frick, G.; Raje, S.; Forlow, S.B.; Balliet, C.; Burczynski, M.E.; Reinhart, P.H.; Wan, H.I.; Pangalos, M.N.; Jacobsen, J.S. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gammasecretase for the treatment of Alzheimer's disease. J. Pharmacol. Exp. Ther., 2009, 331, 598-608.
41. Gillman, K.W.; Starrett, J.E.; Parker, M.F.; Xie, K.; Bronson, J.J.; Marcin, L.R.; McElhone, K.E.; Bergstrom, C.P.; Mate, R.A.; Williams, R.; Meredith, J.E.; Burton, C.R.; Barten, D.M.; Toyn, J.H.; Roberts, S.B.; Lentz, K.A.; Houston, J.G.; Zaczek, R.; Albright, C.F.; Decicco, C.P.; Macor, J.E.; Olson, R.E. Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable -Secretase Inhibitor. ACS Med. Chem. Lett., 2010, 1, 120-124.
42. Glickman, J.F.; Wu, X.; Mercuri, R.; Illy, C.; Bowen, B.R.; He, Y.; Sills, M. A comparison of ALPHAScreen, TR-FRET, and TRF as assay methods for FXR nuclear receptors. J. Biomol. Screen., 2002, 7, 3-10.